

Murat O Arcasoy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1386607/publications.pdf>

Version: 2024-02-01

17
papers

901
citations

933447

10
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

1277
citing authors

#	ARTICLE	IF	CITATIONS
1	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. <i>Blood Advances</i> , 2020, 4, 4282-4291.	5.2	77
2	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
3	Arterial thrombosis and second cancer in MPNs. <i>Blood</i> , 2020, 135, 301-302.	1.4	2
4	Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era. <i>Blood</i> , 2020, 136, 52-53.	1.4	1
5	<i>ZCCHC8</i> , the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation. <i>Genes and Development</i> , 2019, 33, 1381-1396.	5.9	85
6	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	1.4	123
7	A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families. <i>Annals of Hematology</i> , 2019, 98, 1789-1791.	1.8	4
8	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. <i>Blood</i> , 2019, 134, 2943-2943.	1.4	4
9	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. <i>Blood</i> , 2018, 132, 4282-4282.	1.4	7
10	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018, 132, 3032-3032.	1.4	6
11	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	1.4	39
12	Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome. <i>Annals of Hematology</i> , 2017, 96, 1589-1590.	1.8	2
13	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 432-440.	2.0	127
14	The clinical and laboratory evaluation of the patient with erythrocytosis. <i>European Journal of Internal Medicine</i> , 2015, 26, 297-302.	2.2	33
15	Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. <i>European Respiratory Journal</i> , 2014, 44, 178-187.	6.7	161
16	Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. <i>Clinical Cancer Research</i> , 2005, 11, 20-7.	7.0	58
17	Expression of erythropoietin receptor splice variants in human cancer. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 999-1007.	2.1	109